Aquatic Capital Management LLC Increases Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Aquatic Capital Management LLC raised its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 225.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 113,405 shares of the company's stock after buying an additional 78,605 shares during the quarter. Aquatic Capital Management LLC owned 0.07% of Revolution Medicines worth $4,960,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of RVMD. IFP Advisors Inc acquired a new position in shares of Revolution Medicines during the 4th quarter valued at $34,000. Sterling Capital Management LLC increased its stake in Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after purchasing an additional 1,613 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of Revolution Medicines by 521.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after purchasing an additional 3,178 shares in the last quarter. Finally, Avanza Fonder AB acquired a new stake in shares of Revolution Medicines in the 4th quarter valued at about $173,000. 94.34% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Mark A. Goldsmith sold 11,738 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $458,251.52. Following the completion of the transaction, the insider now directly owns 441,564 shares of the company's stock, valued at $17,238,658.56. This trade represents a 2.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at $4,489,834.24. The trade was a 1.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,660 shares of company stock valued at $650,406 over the last quarter. Company insiders own 8.00% of the company's stock.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded up $0.26 on Thursday, reaching $40.64. 1,555,469 shares of the company traded hands, compared to its average volume of 1,448,703. The firm has a market capitalization of $7.56 billion, a PE ratio of -11.32 and a beta of 1.37. The company has a 50 day moving average of $37.36 and a 200 day moving average of $43.90. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). As a group, analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on RVMD. UBS Group increased their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Stifel Nicolaus cut their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $59.00 price target on shares of Revolution Medicines in a research note on Tuesday, April 8th. HC Wainwright raised their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Finally, Wedbush restated an "outperform" rating and issued a $67.00 target price on shares of Revolution Medicines in a report on Monday. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $66.67.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.